Drug Trial Radar · NCT07922733
Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Available
Enrollment
Not stated
Start
Not stated
Primary completion
Not stated
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Expanded access
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Brelovitug is designed to target or bind to a key protein on the surface of hepatitis D and hepatitis B viruses, known as the hepatitis B surface antigen (HBsAg). By targeting this protein, brelovitug may help neutralize virus particles and support their removal from the bloodstream. The aim of this expanded-access program (EAP) is to make brelovitug available to patients with Chronic Hepatitis D (CHD) who are in medical need, cannot benefit from any other comparable authorized treatment, and cannot participate in any available clinical trial.
Conditions
- Chronic Hepatitis, Delta Virus
Interventions
BrelovitugBiological
Brelovitug (BJT-778) is an investigational, fully human monoclonal antibody targeting hepatitis B surface antigen (HBsAg). Eligible patients with chronic hepatitis D (CHD) will receive brelovitug 300 mg administered as a single subcutaneous injection once weekly in the abdomen, upper arm, or thigh. Treatment may be self-administered by appropriately trained patients or administered by healthcare professionals. Treatment will continue as long as the patient derives clinical benefit, as determined by the treating physician, or until treatment discontinuation criteria are met.
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Available
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.